← Leaderboards
Sun Young Lee
University Of Southern California
$2,032,954
Attributed
$2,032,954
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $658.5K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,032,954 · 3
By mechanism
R01$1,135,383 · 1
R21$480,140 · 1
R56$417,431 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Amani A Fawzi$9,595,823
- Amir H Kashani$11,509,148
- John S Oghalai$16,161,936
- Mahnaz Shahidi$15,528,269
- Rohit Varma$80,906,314
Others in their field
Other Rising Stars on “Modification”
- Daofeng Li · Salk Institute For Biological Studies$9,887,266
- Cathryn Peltz · Henry Ford Health + Michigan State University Health Sciences$7,977,678
- Anil Gupta · Scripps Research Institute, The$7,340,144
- Bruxanne El-Kammash · University Of Chicago$7,281,050
- Hong-Ngoc B. Nguyen · University Of Minnesota$6,812,121
- Lidia Minguez Alarcon · Brigham And Women'S Hospital$4,210,660
Research focus
ModificationRetinaInnovationMicrornasNovel StrategiesPublic HealthExosomeInjectionsExtracellular VesiclesLigandsNanosizedBindingPathologicPhysiologicalBlindnessAcidsInflammationChoroidal NeovascularizationCell CommunicationDiabetic RetinopathyCellsIntegrinsMouse ModelRgd (Sequence)
Grant awards (5)
Extracellular vesicle-based intraocular therapy combined with active targeting of ocular neovascularization$460,963
R01 · FY2025 · EY · contact PI
Extracellular vesicle-based intraocular therapy combined with active targeting of ocular neovascularization$197,526
R01 · FY2025 · EY · contact PI
Extracellular vesicle-based intraocular therapy combined with active targeting of ocular neovascularization$476,894
R01 · FY2024 · EY · contact PI
Extracellular Vesicle Therapy for Diabetic Retinopathy$480,140
R21 · FY2023 · EY · contact PI
Exosome based intraocular therapy combined with active targeting of ocular neovascularization$417,431
R56 · FY2022 · EY · contact PI